Asundexian is an experimental, once-daily oral anticoagulant developed that targets Factor XIa (FXIa), a protein in the blood clotting process.
By inhibiting FXIa, the drug aims to prevent the formation of dangerous blood clots while maintaining the body’s natural ability to stop bleeding after an injury.
Factor XIa contributes to clot propagation via the intrinsic (contact activation) pathway and the thrombin amplification loop, but has a limited role in the initiation phase of hemostasis through the extrinsic pathway.
Asundexian inhibits FXIa with high potency and selectivity, reducing thrombin generation and prolonging aPTT without significantly affecting hemostasis.
At 50 mg daily, it achieves >90% FXIa inhibition.
It is administered once daily (50 mg), has a terminal half-life of 16-18 hours, and less than 15% renal elimination.
In the Phase III OCEANIC-STROKE trial, asundexian reduced the risk of recurrent ischemic strokes by 26% compared to a placebo in patients who had recently experienced a non-cardioembolic stroke or mini-stroke (TIA).
This benefit was achieved without increasing the risk of major bleeding.
The Phase III OCEANIC-AF trial was stopped early in late 2023 because asundexian was found to be inferior to apixaban (Eliquis) at preventing strokes in patients with atrial fibrillation.
While it caused significantly less bleeding, it did not provide enough protection against clots in this high-risk population.
Designated for secondary stroke prevention.
Atrial compared asundexian 50 mg to standard-dose apixaban in 14,810 high-risk AF patients was stopped early by the data that stroke or systemic embolism was nearly 4-fold higher with asundexian vs. apixaban (1.3% vs. 0.4%).
Major bleeding was significantly lower with asundexian (0.2% vs. 0.7%).
Asundexian cannot replace apixaban for stroke prevention in AF, the bleeding benefit did not offset the substantial increase in thromboembolic events
OCEANIC-AF illustrates the early and sustained divergence in stroke/systemic embolism favoring apixaban:
Noncardioembolic Ischemic Stroke-OCEANIC-STROKE (Phase 3, NEJM 2026 study).
This trial randomized 12,327 patients with recent noncardioembolic ischemic stroke or high-risk TIA to asundexian 50 mg or placebo, added to antiplatelet therapy:
Ischemic stroke was significantly reduced with asundexian (6.2% vs. 8.4%.
The composite of cardiovascular death, MI, or stroke was also lower.
Disabling or fatal stroke was reduced.
Major bleeding was not increased (1.9% vs. 1.7%).
The OCEANIC-STROKE results are shown in the following figure:
PACIFIC-AF: Asundexian 20 mg and 50 mg produced significantly less bleeding than apixaban in AF patients, providing rationale for phase 3 testing.
PACIFIC-Stroke: No significant difference vs. placebo on the primary composite endpoint, though post-hoc analyses suggested benefit in patients with atherosclerotic stroke subtypes.
Pooled phase 2 bleeding analysis confirmed asundexian’s favorable bleeding profile compared to apixaban and similar bleeding rates to placebo when added to antiplatelet therapy.
Among patients with non-cardioembolic ischemic stroke or high risk TIA treated with anti-platelet therapy, asundexian at a daily dose of 50 mg resulted in the lower risk of a ischemic stroke and major cardiovascular events, and than placebo, without a higher risk of major bleeding (OCEANIC-STROKE investigators).
Asundexian represents a proof-of-concept for FXIa inhibition as a therapeutic strategy, but its clinical utility is indication-dependent.
It failed in AF (inferior to apixaban for stroke prevention despite less bleeding) but succeeded in noncardioembolic stroke secondary prevention (reduced ischemic stroke without excess bleeding when added to antiplatelet therapy).
Asundexian is not currently FDA-approved.